HTA bodies eager for EMA disclosure of clinical trial data
This article was originally published in SRA
Executive Summary
It's not only competitors and independent researchers that are keeping a watchful eye on EU plans to require the disclosure of full clinical trial data on new drugs. Health technology assessment (HTA) bodies such as Germany's IQWiG are closely monitoring developments on this front, and are particularly keen to see the clinical trial reports that the European Medicines Agency proposes to publish proactively from January next year.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.